Built for investors and grounded in the latest healthcare data, Qsight Alpha consistently outperforms consensus. It offers unparalleled visibility and precise insights into the sales performance of companies in the MedTech sector through monthly and quarterly tracking of manufacturers.
Guidepoint Qsight Alpha is a powerful tool designed specifically for institutional investors, using the largest datasets available to provide near real-time insights into manufacturer and product-level performance.
Qsight Alpha
With Qsight Alpha, investors can confidently navigate the complexities of the MedTech market, leveraging robust data to identify trends and opportunities ahead of the competition. By staying informed and proactive, investors using Qsight Alpha can capitalize on emerging market trends and position themselves strategically for success.
To use Qsight Alpha, simply access the platform to track monthly and quarterly sales data. This allows you to see beyond standard market consensus with greater accuracy. As an indispensable tool for investors, Qsight Alpha provides precise and predictive revenue visibility to make smarter, data-driven investment decisions in these rapidly evolving industries.
See How Our Accuracy Compares to Consensus!
Nobody is more accurate, across more names. Here’s how we’ve outperformed quarter after quarter all of the way back to 2020.
How Qsight Alpha Can Maximize Investment Potential
Comprehensive Data Tracking for MedTech & Medical Devices
Frequently Asked Questions
About Qsight Alpha
Qsight Alpha provides detailed insights and data tracking for companies in the MedTech, DME, and aesthetics sectors. Coverage spans company-level and product-specific performance, enabling investors to evaluate trends across multiple segments of the healthcare ecosystem.
Qsight Alpha provides unparalleled visibility into the sales performance of MedTech, non-acute Medical Device, and aesthetic device companies through large-scale purchasing and point-of-sale datasets.
In the MedTech sector, Qsight Alpha stands out due to its ability to consistently outperform consensus forecasts and its access to comprehensive sales data from over 4,500 U.S. healthcare facilities.
In the Aesthetics sector, the platform provides access to manufacturer product-level point-of-sale data, capturing products and treatments sold across more than 3,500 U.S. medical aesthetics locations.
Qsight Alpha also includes pharmacy-level purchase order data reflecting over $2.3 billion annually in medical equipment, devices, and supplies across more than 5,000 U.S. Durable Medical Equipment (DME) pharmacy locations.
Qsight Alpha uses data intelligence derived from purchasing activity across more than 3,500 U.S. healthcare facilities to generate near real-time insights into manufacturer outcomes.
Since 2021, Qsight Alpha has delivered a mean absolute percentage error of 1.68% across its projections and has been directionally accurate on 91.4% of sales estimates when compared to Wall Street consensus. With weekly updates and detailed monthly data extending back to 2010, the platform provides investors with reliable revenue visibility to support informed forecasting and analysis.
Qsight Alpha is designed for institutional investors and strategy teams responsible for forecasting, valuation, and capital allocation within MedTech. The platform translates real-world purchasing activity into sales intelligence at the manufacturer level that supports investment decision-making.
Investors rely on Qsight Alpha to assess revenue momentum, competitive positioning, and underlying performance drivers with greater confidence than narrative-driven or delayed financial sources.
Investors use Qsight Alpha to validate, refine, or challenge consensus expectations by comparing projected performance against observed purchasing behavior across U.S. healthcare facilities. By tracking trends as they develop, Alpha helps identify divergence between market activity and prevailing assumptions. This supports earlier insight into inflection points and strengthens pre-earnings positioning, scenario analysis, and post-earnings interpretation.
Beyond headline comparisons, investors use Qsight Alpha to support data-driven decisions across forecasting cycles and portfolio reviews. By grounding expectations in observed purchasing behavior, Alpha helps teams assess whether near-term performance supports long-term investment theses, particularly during periods of volatility or shifting demand.
Qsight Alpha delivers manufacturer- and product-level visibility into sales performance, including spend, unit volume, and average selling price trends. Data is updated weekly and structured monthly, with historical coverage extending back to 2010. This structure allows investors to move beyond headline revenue figures and evaluate the drivers shaping performance across MedTech categories and peer groups.
At this level, Qsight Alpha supports analysis of core key performance indicators (KPIs) such as pricing trends, volume shifts, utilization rate, and market share across peer manufacturers. These insights are made possible through consistent, large-scale data collection that enables investors to isolate performance drivers and assess competitive strength with greater precision.
Delivering More Than Just Data
Connect with Our Team Today
At Guidepoint Qsight, we empower decisions through unmatched, data-driven insights for the Aesthetics and MedTech industries. Send us your contact information today, and we’ll be in touch to discuss your concerns and overall needs. When it comes to data analytics, we’re the experts you can count on.
The Pulsed Field Ablation Market and the Remaking of AFib Treatment
The AFib ablation catheter market has more than tripled in size since 2018, and spending over the same time period…
The Preventive Era Is Here: What 2025 Gen Z Aesthetics Data Shows
Gen Z has been one of the most-discussed cohorts in medical aesthetics for the better part of a decade. Their…
The Practitioner Is the New Influencer: How Practitioners Are Reshaping Aesthetic Demand
Not long ago, a celebrity endorsement was the fastest path to aesthetic awareness. Drop a treatment name in a magazine…
Why Sales Planning in Medical Aesthetics Needs a Reset in 2026
Here’s what most sales leaders in medical aesthetics know by now: 2026 isn’t going to look like 2021. Or 2022…